Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Multiple ascending dose study of intranasal Memogain in healthy older volunteers
NL-OMON23253Recruiting
- Sponsor
- Neurodyn Life Sciences Inc.
- Start
- Mar 2016
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of benzgalantamine in Alzheimer's disease (AD) (2 arms), sponsored by Neurodyn Life Sciences Inc. Primary endpoints: Treatment-emergent adverse events, Vital sign abnormalities and 13 more. Started Mar 2016; status: recruiting.
02
Drugs
benzgalantamine
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NL-OMON23253.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON23253.